KORU Medical Systems (NASDAQ:KRMD) Stock Rating Upgraded by Wall Street Zen

KORU Medical Systems (NASDAQ:KRMD - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

A number of other research analysts also recently issued reports on the stock. Piper Sandler restated a "neutral" rating and set a $4.50 target price (down from $5.00) on shares of KORU Medical Systems in a research report on Wednesday. Weiss Ratings cut shares of KORU Medical Systems from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, September 29th. Zacks Research cut shares of KORU Medical Systems from a "strong-buy" rating to a "hold" rating in a research report on Friday, October 30th. Finally, Craig Hallum reissued a "buy" rating and set a $6.00 price target on shares of KORU Medical Systems in a research note on Thursday, August 6th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $6.50.

KORU Medical Systems Stock Up 0.3%

NASDAQ:KRMD traded up $0.01 during trading hours on Friday, hitting $3.70. 219,097 shares of the stock were exchanged, compared to its average volume of 180,405. The company has a market capitalization of $160.51 million, a P/E ratio of -185.00 and a beta of 0.47. The company's 50 day moving average is $3.15 and its two-hundred day moving average is $3.92. KORU Medical Systems has a twelve month low of $2.86 and a twelve month high of $6.61.

KORU Medical Systems (NASDAQ:KRMD - Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.02) by $0.04. The company had revenue of $11.57 million during the quarter, compared to the consensus estimate of $11.33 million. KORU Medical Systems had a negative return on equity of 4.62% and a negative net margin of 1.78%. On average, equities research analysts expect that KORU Medical Systems will post -0.02 EPS for the current year.

Insider Activity

In related news, insider Adam Kalbermatten purchased 32,000 shares of the stock in a transaction dated Tuesday, September 8th. The stock was bought at an average cost of $3.16 per share, with a total value of $101,120.00. Following the purchase, the insider directly owned 394,017 shares in the company, valued at $1,245,093.72. The trade was a 8.84% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 18.50% of the company's stock.

Institutional Investors Weigh In On KORU Medical Systems

Large investors have recently bought and sold shares of the company. Algert Global LLC raised its holdings in KORU Medical Systems by 57.2% in the second quarter. Algert Global LLC now owns 22,737 shares of the company's stock worth $95,000 after purchasing an additional 8,270 shares during the period. Bank of America Corp DE boosted its position in shares of KORU Medical Systems by 36.0% during the first quarter. Bank of America Corp DE now owns 37,971 shares of the company's stock worth $164,000 after purchasing an additional 10,045 shares in the last quarter. Vivaldi Capital Management LP boosted its position in shares of KORU Medical Systems by 51.6% during the first quarter. Vivaldi Capital Management LP now owns 29,885 shares of the company's stock worth $129,000 after purchasing an additional 10,172 shares in the last quarter. Sei Investments Co. boosted its position in shares of KORU Medical Systems by 14.8% during the first quarter. Sei Investments Co. now owns 93,772 shares of the company's stock worth $405,000 after purchasing an additional 12,062 shares in the last quarter. Finally, Bard Associates Inc. acquired a new position in shares of KORU Medical Systems in the 2nd quarter valued at $61,000. Institutional investors own 58.60% of the company's stock.

About KORU Medical Systems

KORU Medical Systems develops, manufactures and markets medical devices used to deliver medications under the skin, or subcutaneously. Its products are designed for patients receiving therapies outside traditional infusion settings, including at home. The company's product line includes the Freedom60 and FreedomEDGE ambulatory infusion pumps, Precision Flow Rate Tubing and HIgH-Flo subcutaneous needle sets. These products are used with subcutaneous immunoglobulin and other specialty therapies. Founded in 1980 as Repro Med Systems, the company adopted the name KORU Medical Systems in 2020.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.